Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

STSG 0002

Next Previous
Drug Profile

STSG 0002

Alternative Names: STSG-0002

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Staidson Beijing BioPharmaceuticals
  • Class Antivirals; Gene therapies; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Hepatitis-B(In adults) in China (IV, Injection)
  • 13 Dec 2023 Staidson Beijing Biopharmaceuticals terminates a phase II trial in Hepatitis B (Treatment-experienced) in China (IV) due to the preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited (NCT05760703)
  • 13 Dec 2023 Staidson Beijing Biopharmaceuticals terminates a phase-II clinical trials in Hepatitis B (Treatment-experienced) in China (IV) due to the preliminary effectiveness data observed at present did not meet the expectations, the benefit of the subjects receiving the experimental drug was limited (NCT05760781)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top